Scarica l'app Stockscreener
27.66
0.51%
0.14
Dopo l'orario di chiusura:
27.66
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares - Defense World
Behavioral Patterns of RAPP and Institutional Flows - Stock Traders Daily
Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentSupport Level Holds & Free Discover Fast Growing Stocks - earlytimes.in
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2%Here's What Happened - MarketBeat
Guidance Update: Will Rapport Therapeutics Inc stock continue dividend increasesBull Run & AI Optimized Trade Strategies - moha.gov.vn
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Liquidity Mapping Around (RAPP) Price Events - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? - AOL.com
Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
How sustainable is Rapport Therapeutics Inc. stock dividend payoutWeekly Trade Review & Proven Capital Preservation Tips - Улправда
What technical charts say about Rapport Therapeutics Inc. stockJuly 2025 Weekly Recap & Entry Point Confirmation Signals - Улправда
Can Rapport Therapeutics Inc. stock resist market sell offsMarket Activity Report & Growth Focused Stock Pick Reports - DonanımHaber
Rapport Therapeutics stock holds Buy rating at Goldman Sachs on epilepsy drug efficacy - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $172,890.12 in Stock - MarketBeat
Rapport Therapeutics CEO Sells Shares Worth Over $323K - TradingView — Track All Markets
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Selloffs & Daily Profit Maximizing Tips - Улправда
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $255,170.00 in Stock - MarketBeat
Rapport Therapeutics CSO Sells Shares Under Trading Plan - TradingView — Track All Markets
Rapport Therapeutics Earnings Notes - Trefis
Assessing Rapport Therapeutics (RAPP) Valuation After Positive RAP-219 Phase 2a Epilepsy Data and Phase 3 Plans - Sahm
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4%Here's Why - MarketBeat
Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media
HC Wainwright Issues Optimistic Forecast for RAPP Earnings - Defense World
FY2027 Earnings Forecast for RAPP Issued By HC Wainwright - MarketBeat
Rapport Therapeutics price target raised to $40 from $34 at HC Wainwright - MSN
Rapport Therapeutics, Inc. (RAPP) is up 9.03% in one week: What you should know - MSN
HC Wainwright & Co. Maintains Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) Receives “Buy” Rating from BTIG Research - Defense World
Certain Stock Options of Rapport Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Certain Common Stock of Rapport Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics announces new data, post hox analysis on RAP-219 - MSN
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Yahoo Finance
Affinity Asset Advisors LLC Purchases Shares of 199,643 Rapport Therapeutics, Inc. $RAPP - Defense World
Wall Street Zen Downgrades Rapport Therapeutics (NASDAQ:RAPP) to Sell - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - Defense World
Rapport Therapeutics Announces Positive Phase 2a Post-Hoc Analysis of RAP-219 Demonstrating Early Efficacy in Drug-Resistant Focal Onset Seizures - Quiver Quantitative
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures - The Manila Times
Rapport Therapeutics Announces New Data and Post Hoc - GlobeNewswire
Rapport Therapeutics (RAPP) Valuation After Key Phase 2a Epilepsy Data Presentation Announcement - Sahm
Will Rapport Therapeutics Inc. stock see PE expansionJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - Newser
Is Rapport Therapeutics Inc. stock trading at a premium valuationWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):